PH26909A - Pyrimidine derivatives - Google Patents
Pyrimidine derivatives Download PDFInfo
- Publication number
- PH26909A PH26909A PH36945A PH36945A PH26909A PH 26909 A PH26909 A PH 26909A PH 36945 A PH36945 A PH 36945A PH 36945 A PH36945 A PH 36945A PH 26909 A PH26909 A PH 26909A
- Authority
- PH
- Philippines
- Prior art keywords
- compound
- solution
- formula
- evaporated
- group
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title claims description 9
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims description 38
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 19
- -1 hydroxy, acetoxy Chemical group 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 11
- 229940104302 cytosine Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- KOSYAAIZOGNATQ-UHFFFAOYSA-N o-phenyl chloromethanethioate Chemical compound ClC(=S)OC1=CC=CC=C1 KOSYAAIZOGNATQ-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000012909 foetal bovine serum Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000001980 alanyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005333 aroyloxy group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Description
’ Le] 1 .
The present invention relates to pyrimidine deriv- atives of the formula
Ni, wn?
A
0 N . 1 rR} 0
EF
. 1. Pa wherein R- is hydroxy or esterified hydroxy. and amides and Schiff's bases thereof.
These compounds possess valuable pharmacological properties. In particular, they possess antiviral activity and are useful in the treatment or prophylaxis of viral o5 infections, particularly of retroviral infections, such as visna, HIV and like infections.
Objects of the present invention are the compounds defined above per se and for use as therapeutically active substances: a process for the manufacture of said . compounds: medicaments containing said compounds and the use of said compounds in the control or prevention of illnesses, especially in the treatment or prophylaxis of viral infections, or for the manufacture of medicaments 15 for the treatment or prophylaxis of viral infections.
Duet] . - 2 -
The esterified hydroxy group denoted by rl in formula I can be any conventional esterified hydroxy group, e.g. an alkanoyloxy group, such as acetoxy, propionyloxy or butyryloxy: an aroyloxy group, such as benzoyloxy or substituted-benzoyloxy., e.g. p-toluoyloxy or p-chlorobenzoyloxy. Amides of the compounds of formula I are formed at the 4-amino group with any conventional acyl group, such as an alkanoyl group, e.g. acetyl, propionyl, butyryl or pivaloyl: an aroyl group, e.g. benzoyl: or an acyl group derived from an amino acid, e.g. glycyl, alanyl or lysyl. Schiff's bases of the compounds of formula I are . formed at the 4-amino group with any conventional aldehyde or ketone. such as benzaldehyde, or with a dimethyl- formamide acetal. 1-(2',3'-Dideoxy 2'-fluoro-f -D-arabinofuranosyl)- cytosine (hereinafter DFAC) is a particularly preferred compound of formula I.
According to the process provided by the present invention, the compounds aforesaid are manufactured by (a) removing the 3'-hydroxy group from a compound of the formula
NH,
CO)
A
. 30 10 11
R 0
FE
HO
Spor] ~- 3 wherein gO is an esterified hydroxy group. and, if desired, converting the esterified hydroxy group gO in the product obtained into a hydroxy group, or (b) for the manufacture of a compound of formula 1 in which r! ig esterified hydroxy, esterifying a compound of formula I, in which r' is hydroxy. or (c) for the manufacture of an amide or a Schiff's base of a compound of formula I, converting a compound of formula
I into an amide or into a Schiff's base. : The removal of the 3'-hydroxy group from a compound of formula II in accordance with embodiment (a) of the
Process can be carried out by firstly converting such a compound of formula II into the corresponding sulphonic acid ester, such as the mesylate, by treatment with a sulphonic acid halide, such as methanesulphonyl chloride, conveniently in the presence of an acid-binding agent, og especially a tertiary amine, such as pyridine, and at a low temperature, e.g. 0-5°C. The thus-obtained sulphonic acid ester can then be converted into the 3'-iodide in a known manner, e.g. by treatment with an alkali metal jodide, such as sodium iodide, in a suitable medium, such as an aliphatic ketone, e.g. acetone or 2-butanone, at an elevated temperature, preferably at reflux temperature of the mixture. The resulting 3j'_-jiodide can subsequently be converted into a desired compound of formula I, in which
Rr} igs esterified hydroxy by hydrogenation in the a0 presence of a palladium catalyst. Alternatively, an afore- mentioned 3'-iodide can be treated with tributyl tin hydride in the presence of a free radical initiator, e.g. azobisisobutyronitrile, conveniently in an inert organic solvent, such as an aromatic hydrocarbon, e.g. benzene or toluene, and at an elevated temperature, e.g. about 60°-90°C, to give a desired compound of formula I, in which RE is esterified hydroxy.
LC Gee } - 4 -
A further method for the removal of the 3'-hydroxy group from a compound of formula 11 comprises firstly reacting such a compound with phenyl thionochloro- formate, conveniently in an inert organic solvent, such as acetonitrile, in the presence of an acid-binding agent. such as a tertiary amine, e.g. pyridine or 4-dimethyl- aminopyridine, and at about room temperature, to give a corresponding 3'-O-phenoxythiocarbonyl compound. Such a compound can then be converted into a desired compound of 19 formula I, in which r! is esterified hydroxy. by treatment with tributyltin hydride in the presence of a free radical initiator in a manner analogous to that ’ described earlier. In a preferred embodiment of this method, the compound of formula II is acylated at the 4-amino group prior to the reaction with phenyl thionochloroformate. In this embodiment the product obtained after the treatment with tributyltin hydride is a corresponding amide of a compound of formula I, in which a is esterified hydroxy.
The conversion of the esterified hydroxy group in the product into a hydroxy group can be carried out in a manner known per se, e.g. by treatment with a saturated solution of ammonia in an alkanol, e.g. methanol. When the product carries an acylamino group in the 4-position, this group can be concomitantly converted into an amino group.
A compound of formila I, in which r! is hydroxy, can be esterified in accordance with embodiment (b) of the process to give a compound of formula 1 in which r' is esterified hydroxy. This esterification can be carried out in a manner known per se, e.g. by treating the hydro- chloride salt of a compound of formula I with an appropriate acid halide in an inert organic solvent, such as dimethylformamide. .
. Safe \ . ~ 5
The conversion of a compound of formula I into an amide or into a Schiff's base in accordance with embodi- ment (c) of the process can also be carried out in a manner known per se by treatment with, respectively, an appropriate acylating agent or an appropriate aldehyde, ketone or dimethylformamide acetal.
The starting materials of formula Il can be prepared. e.g. by converting the 3'-acyloxy group in a compound of the formula
NH,
NZ
; 1 0 N ’ IIL 10
R 0
F
R20 . 10 Co wherein R has the significance grven earlier and 2 08 R™ is an acyl group, into a 3'-hydroxy group.
This conversion can be carried out in a known manner, such as by treatment with ammonia or an appropriate amine, such as methylamine, ethylamine, n-propylamine or triethylamine, in a lower alkanol. such as methanol, conveniently at about room temperature. It will be appreciated that the reagent used to effect the conversion and the reaction conditions should be chosen so as not to a5 bring about concomitant conversion of the esterified 10 , : hydroxy group R into hydroxy.
Ye ¢} of . - 6 -
The compounds of formula Ill above are known compounds or analogues of known compounds which can be prepared in a similar manner to the known compounds.
The in vitro antiviral activity of the pyrimidine derivatives provided by the present invention can be demonstrated in the assays described hereinafter. (A) Activity against sheep lentivirus:
This assay uses sheep lentivirus (strain WLC-1) grown in sheep choroid plexus (SCP) cells using a medium which } contains 10% foetal bovine serum. The compounds are tested in 96 well microculture plates. Each well contains 10%scP cells which have been incubated for 48 hours.
Test compounds, dissolved in dimethyl sulphoxide, are added to give a final concentration of 1% dimethyl sulphoxide together with a virus innoculum calculated to produce 100% cytopathic effect in 12 days. After incubation at 37°C for 12 days the plates are fixed and stained with crystal violet. The protection in wells containing test compounds is assessed visually relative to wells containing virus alone and uninfected wells. The activity (MPC) is expressed as the lowest concentration of test compound which produces 100% protection of the infected wells. In this assay. DFAC has a MPC of 2.5uM. (B) Activity against HIV:
This assay uses HTLV-I1I11 (strain RF) grown in C8166 : cells (a human cpa’ T lymphoblastoid line) using RPM1 1640 medium with bicarbonate buffer, antibiotics and 10% foetal bovine serum. A suspension of cells is infected with ten times the TCD of virus and adsorption allowed to proceed for 90 minutes at 37°C. The cells are washed with medium. The test is carried out in 6 ml tissue culture tubes. each tube containing 2 x 10° infected
Jefe) 7 cells in 1.5 ml of medium. Test compounds are dissolved in either aqueous medium or dimethyl sulphoxide, according to solubility, and a 15 nl solution of the substance added.
The cultures are incubated at 37°C for 72 hours in a humidified atmosphere containing 5% carbon dioxide in air.
The cultures are then centrifuged and an aliquot of the supernatant is solubilized and subjected to an antigen capture assay which uses a primary antiserum with particular reactivity against the viral protein 24 and a horseradish peroxidase detection system. Colour generation is measured spectrophotometrically and plotted against the concentration of test substance. The concentration that ’ produces 50% protection is determined (IC 4) -
In the assay described above, DFAC exhibits an ICcq of 1uM.
The pyrimidine derivatives provided by the present invention can be used as medicaments in the form of pharmaceutical preparations which contain them in associ- ation with a compatible pharmaceutical carrier material.
These preparations can be administered orally, e.g. in the form of tablets, dragees, hard gelatine capsules, soft gelatine capsules, solutions, emulsions or suspensions; or og parenterally, e.g. in the form of injection solutions.
The above mentioned carrier material can be a pharmaceutically inert, inorganic or organic carrier. © Examples of such carriers which can be used for tablets, dragees and hard gelatine capsules are lactose, maize starch or derivatives thereof, talc. stearic acid or its salts Examples of suitable carriers for soft gelatine capsules are vegetable oils, waxes, fats, semi-solid and liquid polyols. Suitable carriers for the production of a5 solutions and syrups include, e.g. water, polyols, saccharose, invert sugar and glucose. suitable carriers for injection solutions are, e.g. water, alcohols,
Sed) i - 8 - polyols, glycerine and vegetable oils.
The pharmaceutical preparations can also contain conventional pharmaceutical adjuvants, such as preserving, solubilizing, stabilizing, wetting, emulsifying,
Ea sweetening, colouring or flavouring agents, salts for varying the osmotic pressure, buffers. coating agents or antioxidants. The pharmaceutical preparations can contain other therapeutically valuable substances.
The dosage in which the pyrimidine derivatives pro- vided by the present invention can be administered will ’ vary according to the potency of the particular derivative in question, the condition being treated and the require- ments of the patient as determined by the attending physician. In general, the pyrimidine derivatives can be administered in a daily dosage of about 0.1 to 20, preferably about 0.2 to 15 and particularly about 0.4 to 10 mg/kg body weight, although it will be appreciated that 50 these dosage ranges are given by way of example only and may be varied upwards or downwards.
The pyrimidine derivatives aforesaid can be admini- stered in a single dosage or, preferably, in several sub- : 25 -dosages, e.g. up to six, divided over the day. A suitable unit dosage form for this administration can contain, e.g. from about 0.5 to 300, preferably about. 1.0 to 300 and particularly about 2.0 to about 200 mg of pyrimidine derivatives.
The pharmaceutical preparations can be produced by mixing an aforementioned pyrimidine derivative and, if desired, one or more other therapeutically valuable sub- stances with a compatible pharmaceutical carrier material and, if desired, a pharmaceutical adjuvant and bringing the mixture into a desired administration form. The production of the pharmaceutical preparations can be
Sq) _ 9 - carried out in a manner known per se.
The following Examples illustrates the process provided by the present invention:
Example 1 a) NA solution containing 0.94 g of 1-(3'-0-acetyl-5'-0- _benzoyl-2'-deoxy-2'-fluoro-8-D _arabinofuranosyl)cytosine in 4.9 ml of a 2M solution of ammonia in methanol was stirred for 2 hours. The solution was evaporated to dryness and the residue was recrystallized from ethyl ’ acetate to give 0.64 g of 1-(5' >-benzoyl-2'-deoxy- -2'-fluoro-3-D _arabinofuranosyl)cytosine, m.p. 135-140°C. : b) A solution containing 0.4 g of the product of Example la) in 5.6 ml of dry pyridine was stirred at 0°C while 0.26 g of methanesulphonyl chloride was added dropwise.
The mixture was stirred at 0-5°C for 20 hours and then og treated with 0.1 ml of water. Nfter stirring for 1 hour the mixture was poured into 20 ml of ice/water and extracted with ethyl acetate. The ethyl acetate extracts were washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated to give 0.5 ¢ of 1-(5'_O-benzoyl-2'-deoxy-2'-fluoro-3'-O-methylsulphonyl- _B -D-arabinofuranosyl)cytosine. ¢) A solution of 0.5 ¢ of the product of Example 1b) and 0.9 g of sodium iodide in 12 ml of dry 2-butanone was stirred and boiled under reflux for 16 hours. The resulting suspension was evaporated to dryness and the residue was partitioned between 20 ml of water and 12 ml of ethyl acetate. The layers were separated and the aqueous layer was extracted with ethyl acetate. The ethyl acetate solutions were dried over magnesium sulphate and evaporated. The residue was chromatographed on silica gel with methanol/dichloromethane (1:9). There was obtained
Lequ 10 - 0.2 g of 1-(5'-O-benzoyl-2',3'-dideoxy-2'-fluoro-3"- -iodo-f-D _arabinofuranosyl)cytosine. d) A solution of 0.2 ¢g of the product of Example 1c) in 8 ml of ethanol was treated with a solution of 0.04 g of sodium bicarbonate in 2 ml of water and then hydrogenated in the presence of 0.06 g of 10% palladium-on-carbon catalyst for 24 hours. The catalyst was removed by filtration and the filtrate was evaporated to dryness. The regsidué was partitioned between water and ethyl acetate.
The aqueous phase was separated and back-extracted with ethyl acetate. The ethyl acetate solutions were dried over ’ magnesium sulphate and evaporated. There was obtained 0.14 g of 1-(5'-O-benzoyl-2',3"' -dideoxy-2'~-fluoro-8-D- _arabinofuranosyl)cytosine. e) 0.05 g of the product of Example 1d) was dissolved in 2 ml of a saturated solution of ammonia in methanol. The solution was left to stand for 3 days and was then evaporated to dryness. The residue was dissolved in 2 ml of water and the solution was washed with ethyl acetate.
The aqueous solution was lyophilized for 24 hours to give 0.02 g of DFAC, MS (EI): m/e 229 mm’, 151, 112.
Example 2 a) A solution containing 11.8 g of the product of Example la) in 1180 ml of methanol was stirred and heated to boiling under reflux. The solution was treated with 12 ml of acetic anhydride and then at hourly jntervals for a further 4 hours with 12 ml of acetic anhydride each time.
After 6 hours the solution was evaporated to dryness and the residue was co-evaporated twice with 300 ml of toluene each time, then redissolved in 1 litre of methanol and a5 treated at hourly intervals over a period of 3 hours with 12 ml of acetic ahydride each time. The solution was evaporated to dryness and the residue was dissolved in
Llp] 11 -
dichloromethane.
The solution was washed with water, saturated sodium hydrogen carbonate solution and water, then dried over sodium sulphate and evaporated.
The residue was dried in vacuo to give 12.5 g of N-acetyl-1-
-(5'-O-benzoyl-2'.deoxy-2'-fluoro-f-D-arabinofuranosyl)-
cytosine.
b) A solution containing 10.7 g of the product of Example 2a) and 29.7 ¢g of 4-(dimethylamino)pyridine in 295 ml of
40 acetonitrile was stirred under argon and cooled at 5°C while 5.61 g of phenyl chlorothionocarbonate were added dropwise.
The mixture was stirred at 5°C for a further minutes and then at room temperature for 3 hours.
The. resulting solution was evaporated to dryness and the residue was dissolved in dichloromethane.
The solution was washed with ice-cold water, 1M hydrochloric acid, water, saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, then dried over sodium sulphate and evaporated.
The residue was dried in vacuo to give og 14.2 g of N-acetyl-1-(5'-0O-benzoyl-2'-deoxy-2'-fluoro- _3'-0-phenoxythiocarbonyl-B-D-arabinofuranosyl)cytosine. c) A solution containing 14.1 g¢ of the product of Example 2b) and 0.5 g of azobisisobutyronitrile in 520 ml of dry
55 toluene was stirred while argon was bubbled through the solution for 10 minutes. 11.28 g of tributyltin hydride were added and the introduction of argon was continued for a further 30 minutes.
The mixture was then heated at 75°C under argon for 3 hours.
The solution was evaporated to dryness and the residue was triturated with hexane.
The
: product was filtered off and purified by chromatography on silica gel with methanol/dichloromethane (1:9). There were obtained 6.95 g of N-acetyl-1-(5'-O-benzoyl-2',63' —-dideoxy-2'-fluoro-f-D-arabinofuranosyl)cytosine, m.p.
191-193.5°C, after recrystallization from toluene.
Je) - 12 -- d) NA solution containing 0.5 g of the product of Example 2c) in 50 ml of methanol, which had previously been saturated with ammonia at 0°C, was stirred for 3 days. The solution was evaporated to dryness and the residue was dissolved in 30 ml of water. The aqueous solution was washed with ethyl acetate and then evaporated to dryness.
The residue was recrystallized from ethanol to give 0.18 g of DFAC, m.p. 204-207°C. The mother liquors from the recrystallization were evaporated and the residue was dissolved in distilled water. The aqueous solution was lyophilized and the residue was recrystallized from ethanol to give a second crop of 0.06 g of DFAC, m.p. ’ 199-203°C.
The following Examples illustrate typical pharma- ceutical preparations containing the pyrimidine deriva- tives provided by the present invention as the active ingredient:
Example A
Tablets containing the following ingredients can be prepared in a conventional manner:
Ingredients Per tablet
Active ingredient 10 mg
Lactose 20 mg starch 4 mg pPolyvinylpyrrolidone 0.5 mg
Magnesium stearate 0.5 mg
Tablet weight 35 mg as ,
-~ 13 -
Example B
Ingredients Per capsule
NActive ingredient 25 mg
Lactose 15 mg
Sodium starch glycollate 2.95 mg
Magnesium stearate 0.5 mg capsule fill weight 43 mg oo © 25 ag .
Claims (4)
- Do — 14 — CLAIMS: . 1. Compound of the general formula: PN ne?’ J A 1 pl Pa Ci wherein R* represents hydroxy, acetoxy or benzoyloxy and amides formed at the 4-amino group with an acetyl or benzoyl group.
- 2. 1-(2',3'-Dideoxy-2'—fluoro-B-D-arabino- furanosyl)cytosine.
- 3. A method for treating viral infections which comprises administering to a host in need of such treatment an effective amount of a compound according to claim 1.
- 4. A pharmaceutical composition containing a pyrimidine derivative set forth in claim 1 and a pharmaceutically acceptable carrier material. PETER JAMES MACHIN JOSEPH ARMSTRONG MARTIN GARETH JOHN THOMAS (Inventors)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB878712115A GB8712115D0 (en) | 1987-05-22 | 1987-05-22 | Pyrimidine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
PH26909A true PH26909A (en) | 1992-12-03 |
Family
ID=10617762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH36945A PH26909A (en) | 1987-05-22 | 1988-05-18 | Pyrimidine derivatives |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0292023A3 (en) |
JP (1) | JPS63303992A (en) |
KR (1) | KR880013927A (en) |
CN (1) | CN88103089A (en) |
AU (1) | AU602083B2 (en) |
DK (1) | DK165985C (en) |
FI (1) | FI882303A (en) |
GB (1) | GB8712115D0 (en) |
HU (1) | HU199868B (en) |
IL (1) | IL86394A0 (en) |
IS (1) | IS3344A7 (en) |
MC (1) | MC1934A1 (en) |
MX (1) | MX11493A (en) |
NO (1) | NO171065C (en) |
NZ (1) | NZ224638A (en) |
PH (1) | PH26909A (en) |
PT (1) | PT87550B (en) |
YU (1) | YU46860B (en) |
ZA (1) | ZA883447B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340645C (en) * | 1987-04-17 | 1999-07-13 | Victor E. Marquez | Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus |
US4908440A (en) * | 1987-11-12 | 1990-03-13 | Bristol Myers Company | 2',3'-dideoxy-2'-fluoroarabinopyrimidine nucleosides |
NZ232912A (en) * | 1989-03-17 | 1992-06-25 | Oncogen Ltd Lp | Synergistic composition of nucleoside derivatives for inhibiting hiv |
CA2073063A1 (en) * | 1989-11-06 | 1991-05-07 | Jo Klaveness | Nucleoside derivatives |
AT400953B (en) * | 1994-08-25 | 1996-05-28 | Joern Saischek | PENTOFURANOSIDE DERIVATIVES, THEIR PRODUCTION AND USE |
BR9908270A (en) | 1998-02-25 | 2004-06-29 | Univ Emory | 2-Fluoro-nucleosides, pharmaceutical compositions and their uses |
ES2402597T3 (en) | 2000-10-18 | 2013-05-07 | Gilead Pharmasset Llc | Modified nucleosides for the treatment of viral infections and abnormal cell proliferation |
BR0210594A (en) | 2001-06-22 | 2005-11-01 | Pharmasset Ltd | (beta) -d or (beta) -1,3-halonucleoside |
CN101044151B (en) | 2004-08-23 | 2011-01-19 | 弗·哈夫曼-拉罗切有限公司 | Antiviral 4'-azido-nucleosides |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
JP2010505902A (en) | 2006-10-10 | 2010-02-25 | メディヴィル・アクチエボラーグ | HCV nucleoside inhibitors |
-
1987
- 1987-05-22 GB GB878712115A patent/GB8712115D0/en active Pending
-
1988
- 1988-04-26 DK DK227388A patent/DK165985C/en active
- 1988-05-13 YU YU93288A patent/YU46860B/en unknown
- 1988-05-16 IL IL86394A patent/IL86394A0/en unknown
- 1988-05-16 MX MX1149388A patent/MX11493A/en unknown
- 1988-05-16 NZ NZ224638A patent/NZ224638A/en unknown
- 1988-05-16 ZA ZA883447A patent/ZA883447B/en unknown
- 1988-05-17 AU AU16317/88A patent/AU602083B2/en not_active Ceased
- 1988-05-17 FI FI882303A patent/FI882303A/en not_active Application Discontinuation
- 1988-05-18 PH PH36945A patent/PH26909A/en unknown
- 1988-05-18 HU HU882469A patent/HU199868B/en not_active IP Right Cessation
- 1988-05-19 JP JP63120806A patent/JPS63303992A/en active Pending
- 1988-05-19 IS IS3344A patent/IS3344A7/en unknown
- 1988-05-19 MC MC881980A patent/MC1934A1/en unknown
- 1988-05-20 PT PT87550A patent/PT87550B/en not_active IP Right Cessation
- 1988-05-20 NO NO882233A patent/NO171065C/en unknown
- 1988-05-21 CN CN198888103089A patent/CN88103089A/en active Pending
- 1988-05-21 KR KR1019880006017A patent/KR880013927A/en not_active Application Discontinuation
- 1988-05-24 EP EP88108271A patent/EP0292023A3/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
YU93288A (en) | 1990-04-30 |
PT87550B (en) | 1992-09-30 |
MC1934A1 (en) | 1989-05-19 |
EP0292023A2 (en) | 1988-11-23 |
ZA883447B (en) | 1988-11-22 |
DK227388A (en) | 1988-11-23 |
PT87550A (en) | 1989-05-31 |
JPS63303992A (en) | 1988-12-12 |
DK165985C (en) | 1993-11-08 |
HUT47127A (en) | 1989-01-30 |
NZ224638A (en) | 1990-04-26 |
NO171065C (en) | 1993-01-20 |
AU1631788A (en) | 1988-11-24 |
HU199868B (en) | 1990-03-28 |
IS3344A7 (en) | 1988-11-23 |
NO882233D0 (en) | 1988-05-20 |
NO882233L (en) | 1988-11-23 |
CN88103089A (en) | 1988-12-07 |
KR880013927A (en) | 1988-12-22 |
DK165985B (en) | 1993-02-22 |
FI882303A0 (en) | 1988-05-17 |
GB8712115D0 (en) | 1987-06-24 |
NO171065B (en) | 1992-10-12 |
YU46860B (en) | 1994-06-24 |
DK227388D0 (en) | 1988-04-26 |
AU602083B2 (en) | 1990-09-27 |
IL86394A0 (en) | 1988-11-15 |
MX11493A (en) | 1993-09-01 |
EP0292023A3 (en) | 1989-06-14 |
FI882303A (en) | 1988-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3923784A (en) | Erythromycin a derivatives | |
AU602083B2 (en) | Pyrimidine derivatives | |
JPH01249797A (en) | 2', 3'-dideoxy-2', 2'-difluoronucleotides | |
JPH05222082A (en) | Polycyclic conjugant | |
EP0273277B1 (en) | Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retrovirus | |
US5071983A (en) | Therapeutic nucleosides | |
NO128156B (en) | ||
JPH01149797A (en) | Purine derivative | |
AU616914B2 (en) | Therapeutic necleosides | |
JPH0267295A (en) | Purine derivative | |
EP0044227B1 (en) | 11-alpha-amino androstanes, pharmaceutical compositions containing them and processes for their preparation | |
US3855206A (en) | Adenosine-5{40 -carbohydroxamic esters | |
IL42837A (en) | Cardenolide-3-(2'-desoxy-l-glycosides) and process for their manufacture | |
US3230240A (en) | Fusidic acid and dihydrofusidic acid derivatives | |
US4011221A (en) | S-inosylcysteine and a process for producing the same | |
US5010108A (en) | N-cycloalkylaminoethylbenzamide derivatives, their synthesis and pharmaceutical preparations | |
EP0066467B1 (en) | 11-alpha-amino-androstanes | |
US4497805A (en) | 11α-amino-androstanes | |
US4985451A (en) | Elaiophylin derivatives, the use thereof as pharmaceuticals, and pharmaceuticals containing them | |
US5233029A (en) | Elaiophylin derivatives and a process for the preparation thereof | |
US3504088A (en) | Pharmaceutical composition containing 11-amino-6-morphanthridones | |
US3950323A (en) | Digoxigenine-3-[2',3'-didesoxy-glycosides] and a process for their manufacture | |
US4451405A (en) | 11α-Amino-3β-hydroxy-androstanes | |
JPS6152839B2 (en) | ||
US3872081A (en) | Digitoxigenin rhamnoside cyclocarbonates |